ARK Invest founder Cathie Wood doesn't mind going against the grain. Her exchange-traded funds (ETFs) often buy shares of companies that have fallen significantly.
But Wood has a knack for identifying stocks that could be big winners. She definitely has analysts on her side with some recent purchases. Here are three beaten-down stocks Wood is buying that Wall Street thinks will skyrocket.
1. Arcturus Therapeutics
Shares of Arcturus Therapeutics (ARCT -0.10%) are still more than 60% below the highs from December despite a partial rebound this summer. The steep decline resulted from phase 1/2 clinical data that showed disappointing neutralizing antibody levels produced by Arcturus' COVID-19 vaccine candidate ARCT-021.
Wood believes that Arcturus still has plenty of potential, though. Her ARK Genomic Revolution ETF recently scooped up shares of the vaccine underdog. Analysts also remain confident about Arcturus' prospects. The consensus price target for the stock reflects an upside potential of close to 70%.
Why is there such optimism for Arcturus? The company has another messenger RNA (mRNA) COVID-19 vaccine candidate, ARCT-154, that looks promising in protecting against multiple coronavirus variants.
Arcturus recently began dosing in a phase 3b study of ARCT-154 in Vietnam. The company and its partner, Vinbiocare, expect to file for Emergency Use Authorization (EUA) in the country in December 2021. Arcturus is also evaluating the experimental vaccine in a phase 1/2 study in Singapore.
2. CRISPR Therapeutics
CRISPR Therapeutics' (CRSP -0.55%) shares are down more than 50% from the peak in January. Some of the declines weren't related to anything CRISPR Therapeutics did. However, the durability of response in the company's recent phase 1 data for CAR-T therapy CTX110 disappointed investors.
This gene-editing stock remains one of Wood's favorites, though. The ARK Genomic Revolution ETF and the ARK Innovation ETF have bought shares of CRISPR Therapeutics this month.
Despite the stock's dismal year-to-date performance, Wall Street also likes CRISPR Therapeutics. The average analysts estimate is 66% higher than the biotech's current share price.
CTX110 could still be a winner for CRISPR Therapeutics over the long run. The company and its big partner, Vertex Pharmaceuticals, hope to file for approvals of gene-editing therapy CTX001 in treating rare blood diseases beta-thalassemia and sickle cell disease in 2023.
3. Teladoc Health
Teladoc Health's (TDOC 2.25%) shares are also more than 50% lower than they were earlier this year. The main reason for this major sell-off is investors' concerns about the virtual care leader's slowing membership growth.
Wood doesn't seem to share those concerns. Teladoc remains the No. 1 holding in the ARK Genomic Revolution ETF and the No. 2 holding in the ARK Innovation ETF. Both ETFs have also been adding to their positions in Teladoc this month. So has the ARK Fintech Revolution ETF.
Analysts also continue to be bullish about Teladoc. The consensus Wall Street price target reflects an upside potential of over 40%.
There are several reasons behind the positive outlook for Teladoc. The company continues to deliver strong revenue growth along with increased visits and utilization. Most importantly, Teladoc is still only scratching the surface of its opportunity in the global virtual care market.